

# Johnson & Johnson

## Third Quarter 2024 Other Financial Disclosures Table of Contents

<a href="#">Table 1: Sales by Segment</a>	1
<a href="#">Table 2: Sales by Geographic Area</a>	2
<a href="#">Table 3: Sales of Key Products/Franchises</a>	3 - 7
<a href="#">Table 3a: Supplemental Sales Reconciliation</a>	8
<a href="#">Table 4: Condensed Consolidated Statement of Earnings - QTD</a>	9
<a href="#">Table 5: Condensed Consolidated Statement of Earnings - YTD</a>	10
<a href="#">Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD</a>	11
<a href="#">Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD</a>	12
<a href="#">Table 8: Non-GAAP Adjusted Net Earnings</a>	13
<a href="#">Table 9: Non-GAAP IBT and R&amp;D Expense by Segment - QTD</a>	14
<a href="#">Table 10: Non-GAAP IBT and R&amp;D Expense by Segment - YTD</a>	15
<a href="#">Table 11: Non-GAAP P&amp;L Reconciliation</a>	16

Johnson & Johnson and Subsidiaries

Supplementary Sales Data

(Unaudited; Dollars in Millions)

THIRD QUARTER

	2024	2023	Total	Percent Change	
				Operations	Currency
Sales to customers by segment of business					
Innovative Medicine <sup>(1)</sup>					
U.S.	\$ 8,871	8,249	7.5 %	7.5	-
International	5,709	5,644	1.2	4.4	(3.2)
	<b>14,580</b>	<b>13,893</b>	4.9	6.3	(1.4)
Innovative Medicine excluding COVID-19 Vaccine <sup>(1)</sup>					
U.S.	8,871	8,249	7.5	7.5	-
International	5,708	5,603	1.9	5.2	(3.3)
	<b>14,579</b>	<b>13,852</b>	5.2	6.6	(1.4)
MedTech					
U.S.	4,038	3,747	7.8	7.8	-
International	3,853	3,711	3.9	5.0	(1.1)
	<b>7,891</b>	<b>7,458</b>	5.8	6.4	(0.6)
U.S.	12,909	11,996	7.6	7.6	-
International	9,562	9,355	2.2	4.6	(2.4)
Worldwide	<b>22,471</b>	<b>21,351</b>	5.2	6.3	(1.1)
U.S.	12,909	11,996	7.6	7.6	-
International	9,561	9,314	2.7	5.1	(2.4)
Worldwide excluding COVID-19 Vaccine <sup>(1)</sup>	\$ <b>22,470</b>	<b>21,310</b>	5.4 %	6.5	(1.1)

NINE MONTHS

	2024	2023	Total	Percent Change	
				Operations	Currency
Sales to customers by segment of business					
Innovative Medicine <sup>(1)</sup>					
U.S.	\$ 24,993	23,090	8.2 %	8.2	-
International	17,639	17,947	(1.7)	2.1	(3.8)
	<b>42,632</b>	<b>41,037</b>	3.9	5.5	(1.6)
Innovative Medicine excluding COVID-19 Vaccine <sup>(1)</sup>					
U.S.	24,993	23,090	8.2	8.2	-
International	17,441	16,874	3.4	7.4	(4.0)
	<b>42,434</b>	<b>39,964</b>	6.2	7.9	(1.7)
MedTech					
U.S.	12,105	11,345	6.7	6.7	-
International	11,564	11,382	1.6	4.7	(3.1)
	<b>23,669</b>	<b>22,727</b>	4.1	5.7	(1.6)
U.S.	37,098	34,435	7.7	7.7	-
International	29,203	29,329	(0.4)	3.1	(3.5)
Worldwide	<b>66,301</b>	<b>63,764</b>	4.0	5.6	(1.6)
U.S.	37,098	34,435	7.7	7.7	-
International	29,005	28,256	2.7	6.3	(3.6)
Worldwide excluding COVID-19 Vaccine <sup>(1)</sup>	\$ <b>66,103</b>	<b>62,691</b>	5.4 %	7.1	(1.7)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

<sup>(1)</sup> Refer to supplemental sales information schedules

Johnson & Johnson and Subsidiaries  
Supplementary Sales Data

(Unaudited; Dollars in Millions)	THIRD QUARTER				
	2024	2023	Total	Percent Change	
				Operations	Currency
Sales to customers by geographic area					
U.S.	\$ 12,909	11,996	7.6 %	7.6	-
Europe	4,914	4,727	4.0	3.0	1.0
Western Hemisphere excluding U.S.	1,173	1,171	0.3	20.3	(20.0)
Asia-Pacific, Africa	3,475	3,457	0.5	1.5	(1.0)
International	9,562	9,355	2.2	4.6	(2.4)
Worldwide	\$ 22,471	21,351	5.2 %	6.3	(1.1)

(Unaudited; Dollars in Millions)	NINE MONTHS				
	2024	2023	Total	Percent Change	
				Operations	Currency
Sales to customers by geographic area					
U.S.	\$ 37,098	34,435	7.7 %	7.7	-
Europe	15,291	15,448	(1.0)	(0.7)	(0.3)
Western Hemisphere excluding U.S.	3,579	3,383	5.8	21.4	(15.6)
Asia-Pacific, Africa	10,333	10,498	(1.6)	2.8	(4.4)
International	29,203	29,329	(0.4)	3.1	(3.5)
Worldwide	\$ 66,301	63,764	4.0 %	5.6	(1.6)

Johnson & Johnson and Subsidiaries  
Supplementary Sales Data

(Unaudited; Dollars in Millions)	THIRD QUARTER				
	2024	2023	Total	Percent Change	
				Operations	Currency
Sales to customers by geographic area (ex. COVID-19 Vaccine)					
U.S.*	\$ 12,909	11,996	7.6 %	7.6	-
Europe <sup>(1)</sup>	4,913	4,686	4.8	3.8	1.0
Western Hemisphere excluding U.S.*	1,173	1,171	0.3	20.3	(20.0)
Asia-Pacific, Africa*	3,475	3,457	0.5	1.5	(1.0)
International	9,561	9,314	2.7	5.1	(2.4)
Worldwide	\$ 22,470	21,310	5.4 %	6.5	(1.1)

(Unaudited; Dollars in Millions)	NINE MONTHS				
	2024	2023	Total	Percent Change	
				Operations	Currency
Sales to customers by geographic area (ex. COVID-19 Vaccine)					
U.S.*	\$ 37,098	34,435	7.7 %	7.7	-
Europe <sup>(1)</sup>	15,093	14,375	5.0	5.3	(0.3)
Western Hemisphere excluding U.S.*	3,579	3,383	5.8	21.4	(15.6)
Asia-Pacific, Africa*	10,333	10,498	(1.6)	2.8	(4.4)
International	29,005	28,256	2.7	6.3	(3.6)
Worldwide	\$ 66,103	62,691	5.4 %	7.1	(1.7)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

<sup>(1)</sup> Refer to supplemental sales information schedules

\*No COVID-19 Vaccine sales

INNOVATIVE MEDICINE SEGMENT <sup>(2)</sup>

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
THIRD QUARTER					
	2024	2023	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>IMMUNOLOGY</b>					
US	\$ 3,068	3,193	-3.9%	-3.9%	-
Intl	1,552	1,656	-6.2%	-2.1%	-4.1%
WW	4,621	4,849	-4.7%	-3.3%	-1.4%
<b>REMICADE</b>					
US	281	296	-5.4%	-5.4%	-
US Exports <sup>(3)</sup>	27	38	-28.9%	-28.9%	-
Intl	112	127	-11.5%	-6.5%	-5.0%
WW	419	461	-9.1%	-7.7%	-1.4%
<b>SIMPONI / SIMPONIARIA</b>					
US	299	310	-3.7%	-3.7%	-
Intl	218	319	-31.8%	-23.3%	-8.5%
WW	516	629	-18.0%	-13.6%	-4.4%
<b>STELARA</b>					
US	1,770	1,912	-7.5%	-7.5%	-
Intl	906	951	-4.8%	-2.3%	-2.5%
WW	2,676	2,864	-6.6%	-5.7%	-0.9%
<b>TREMFYA</b>					
US	691	634	9.1%	9.1%	-
Intl	316	258	22.6%	26.9%	-4.3%
WW	1,007	891	13.0%	14.3%	-1.3%
<b>OTHER IMMUNOLOGY</b>					
US	1	2	-45.6%	-45.6%	-
Intl	0	0	-	-	-
WW	1	2	-45.6%	-45.6%	-
<b>INFECTIOUS DISEASES</b>					
US	365	360	1.5%	1.5%	-
Intl	471	500	-5.7%	-5.1%	-0.6%
WW	836	859	-2.7%	-2.4%	-0.3%
<b>COVID-19 VACCINE</b>					
US	0	0	-	-	-
Intl	1	41	-97.7%	-98.9%	1.2%
WW	1	41	-97.7%	-98.9%	1.2%
<b>EDURANT / ritonavirine</b>					
US	8	9	-15.8%	-15.8%	-
Intl	323	287	12.3%	11.4%	0.9%
WW	330	297	11.5%	10.6%	0.9%
<b>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</b>					
US	355	345	2.8%	2.8%	-
Intl	94	102	-6.9%	-3.0%	-3.9%
WW	449	447	0.6%	1.5%	-0.9%
<b>OTHER INFECTIOUS DISEASES</b>					
US	3	5	-52.2%	-52.2%	-
Intl	53	69	-23.2%	-20.5%	-2.7%
WW	55	74	-25.4%	-22.9%	-2.5%

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
NINE MONTHS					
	2024	2023	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>IMMUNOLOGY</b>					
US	\$ 8,499	8,506	-0.1%	-0.1%	-
Intl	5,090	4,951	2.8%	7.3%	-4.5%
WW	13,590	13,457	1.0%	2.6%	-1.6%
<b>REMICADE</b>					
US	778	849	-8.5%	-8.5%	-
US Exports <sup>(3)</sup>	89	112	-20.5%	-20.5%	-
Intl	380	449	-15.4%	-11.3%	-4.1%
WW	1,246	1,410	-11.6%	-10.3%	-1.3%
<b>SIMPONI / SIMPONIARIA</b>					
US	820	866	-5.3%	-5.3%	-
Intl	787	829	-5.1%	4.1%	-9.2%
WW	1,607	1,695	-5.2%	-0.7%	-4.5%
<b>STELARA</b>					
US	5,021	5,180	-3.1%	-3.1%	-
Intl	2,991	2,925	2.2%	5.4%	-3.2%
WW	8,012	8,105	-1.2%	0.0%	-1.2%
<b>TREMFYA</b>					
US	1,789	1,490	20.1%	20.1%	-
Intl	932	747	24.7%	29.6%	-4.9%
WW	2,721	2,237	21.6%	23.3%	-1.7%
<b>OTHER IMMUNOLOGY</b>					
US	3	9	-66.8%	-66.8%	-
Intl	0	0	-	-	-
WW	3	9	-66.8%	-66.8%	-
<b>INFECTIOUS DISEASES</b>					
US	1,023	1,147	-10.8%	-10.8%	-
Intl	1,599	2,420	-33.9%	-33.4%	-0.5%
WW	2,622	3,566	-26.5%	-26.1%	-0.4%
<b>COVID-19 VACCINE</b>					
US	0	0	-	-	-
Intl	198	1,073	-81.6%	-81.6%	0.0%
WW	198	1,073	-81.6%	-81.6%	0.0%
<b>EDURANT / ritonavirine</b>					
US	24	26	-10.0%	-10.0%	-
Intl	926	816	13.5%	13.3%	0.2%
WW	950	843	12.7%	12.6%	0.1%
<b>PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</b>					
US	990	1,105	-10.5%	-10.5%	-
Intl	315	310	1.8%	4.3%	-2.5%
WW	1,305	1,415	-7.8%	-7.2%	-0.6%
<b>OTHER INFECTIOUS DISEASES</b>					
US	10	15	-37.7%	-37.7%	-
Intl	160	220	-27.4%	-24.2%	-3.2%
WW	169	235	-28.0%	-25.1%	-2.9%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER				
	2024	2023	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>NEUROSCIENCE</b>					
US	1,094	1,036	5.6%	5.6%	-
Intl	662	706	-6.2%	-3.9%	-2.3%
WW	1,755	1,742	0.8%	1.7%	-0.9%
CONCERTA / Methylphenidate					
US	26	57	-55.0%	-55.0%	-
Intl	117	133	-11.9%	-8.5%	-3.4%
WW	142	189	-24.8%	-22.5%	-2.3%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA					
US	780	730	6.8%	6.8%	-
Intl	269	299	-10.1%	-8.3%	-1.8%
WW	1,049	1,029	1.9%	2.4%	-0.5%
SPRAVATO					
US	243	154	56.8%	56.8%	-
Intl	42	29	44.6%	47.4%	-2.8%
WW	284	183	54.9%	55.3%	-0.4%
OTHER NEUROSCIENCE					
US	46	94	-51.4%	-51.4%	-
Intl	235	245	-4.4%	-2.0%	-2.4%
WW	281	340	-17.4%	-15.7%	-1.7%
<b>ONCOLOGY</b>					
US	2,816	2,219	26.9%	26.9%	-
Intl	2,565	2,313	10.9%	14.3%	-3.4%
WW	5,380	4,533	18.7%	20.5%	-1.8%
CARVYKTI					
US	258	140	84.9%	84.9%	-
Intl	27	12	*	*	*
WW	286	152	87.7%	87.6%	0.1%
DARZALEX					
US	1,684	1,369	23.0%	23.0%	-
Intl	1,332	1,130	17.9%	22.8%	-4.9%
WW	3,016	2,499	20.7%	22.9%	-2.2%
ERLEADA					
US	337	288	17.1%	17.1%	-
Intl	453	342	32.4%	34.0%	-1.6%
WW	790	631	25.4%	26.3%	-0.9%
IMBRUVICA					
US	259	264	-1.9%	-1.9%	-
Intl	494	545	-9.2%	-7.2%	-2.0%
WW	753	808	-6.8%	-5.5%	-1.3%
TECVAYLI					
US	105	93	13.5%	13.5%	-
Intl	30	19	54.2%	59.4%	-5.2%
WW	135	112	20.6%	21.4%	-0.8%
ZYTIGA / abiraterone acetate					
US	5	16	-66.0%	-66.0%	-
Intl	144	199	-27.1%	-24.4%	-2.7%
WW	150	214	-30.0%	-27.5%	-2.5%
OTHER ONCOLOGY					
US	168	50	*	*	-
Intl	83	67	24.8%	27.6%	-2.8%
WW	250	117	*	*	*

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	NINE MONTHS				
	2024	2023	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>NEUROSCIENCE</b>					
US	3,250	3,043	6.8%	6.8%	-
Intl	2,090	2,296	-8.9%	-4.8%	-4.1%
WW	5,340	5,339	0.0%	1.8%	-1.8%
CONCERTA / Methylphenidate					
US	101	191	-47.5%	-47.5%	-
Intl	382	412	-7.3%	-2.9%	-4.4%
WW	482	603	-20.0%	-17.0%	-3.0%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA					
US	2,329	2,164	7.6%	7.6%	-
Intl	830	940	-11.7%	-8.7%	-3.0%
WW	3,159	3,104	1.8%	2.7%	-0.9%
SPRAVATO					
US	660	409	61.2%	61.2%	-
Intl	120	74	62.9%	65.0%	-2.1%
WW	780	483	61.5%	61.8%	-0.3%
OTHER NEUROSCIENCE					
US	161	278	-42.1%	-42.1%	-
Intl	759	870	-12.8%	-7.4%	-5.4%
WW	920	1,149	-19.9%	-15.8%	-4.1%
<b>ONCOLOGY</b>					
US	7,835	6,177	26.8%	26.8%	-
Intl	7,450	6,865	8.5%	12.6%	-4.1%
WW	15,284	13,043	17.2%	19.3%	-2.1%
CARVYKTI					
US	565	324	74.6%	74.6%	-
Intl	63	17	*	*	*
WW	629	341	84.3%	84.2%	0.1%
DARZALEX					
US	4,789	3,882	23.4%	23.4%	-
Intl	3,797	3,312	14.6%	19.9%	-5.3%
WW	8,586	7,194	19.3%	21.8%	-2.5%
ERLEADA					
US	940	778	20.8%	20.8%	-
Intl	1,275	961	32.6%	35.6%	-3.0%
WW	2,215	1,740	27.3%	29.0%	-1.7%
IMBRUVICA					
US	770	796	-3.2%	-3.2%	-
Intl	1,537	1,681	-8.5%	-6.1%	-2.4%
WW	2,307	2,476	-6.8%	-5.2%	-1.6%
TECVAYLI					
US	310	232	34.0%	34.0%	-
Intl	93	37	*	*	*
WW	403	269	49.6%	50.0%	-0.4%
ZYTIGA / abiraterone acetate					
US	25	41	-38.0%	-38.0%	-
Intl	470	646	-27.1%	-22.8%	-4.3%
WW	496	686	-27.8%	-23.7%	-4.1%
OTHER ONCOLOGY					
US	435	125	*	*	-
Intl	214	211	2.0%	4.8%	-2.8%
WW	649	336	93.4%	95.1%	-1.7%

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
THIRD QUARTER					
	2024	2023	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>PULMONARY HYPERTENSION</b>					
US	815	680	20.0%	20.0%	-
Intl	287	274	4.5%	9.7%	-5.2%
WW	1,102	954	15.6%	17.0%	-1.4%
<b>QPSLIMIT</b>					
US	406	323	25.4%	25.4%	-
Intl	165	166	-0.2%	1.7%	-1.9%
WW	571	490	16.8%	17.4%	-0.6%
<b>UPTRAVI</b>					
US	379	336	12.7%	12.7%	-
Intl	80	66	21.8%	28.2%	-6.4%
WW	458	402	14.2%	15.2%	-1.0%
<b>OTHER PULMONARY HYPERTENSION</b>					
US	32	20	54.0%	54.0%	-
Intl	40	42	-3.9%	12.4%	-16.3%
WW	72	63	15.0%	25.9%	-10.9%
<b>CARDIOVASCULAR / METABOLISM / OTHER</b>					
US	713	763	-6.5%	-6.5%	-
Intl	170	194	-11.9%	-10.0%	-1.9%
WW	884	957	-7.6%	-7.2%	-0.4%
<b>XARELTO</b>					
US	592	625	-5.2%	-5.2%	-
Intl	-	-	-	-	-
WW	592	625	-5.2%	-5.2%	-
<b>OTHER</b>					
US	121	139	-12.2%	-12.2%	-
Intl	170	194	-11.9%	-10.0%	-1.9%
WW	292	332	-12.0%	-10.9%	-1.1%
<b>TOTAL INNOVATIVE MEDICINE</b>					
US	8,871	8,249	7.5%	7.5%	-
Intl	5,709	5,644	1.2%	4.4%	-3.2%
WW	\$ 14,580	\$ 13,893	4.9%	6.3%	-1.4%

REPORTED SALES vs. PRIOR PERIOD (\$MM)					
NINE MONTHS					
	2024	2023	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>PULMONARY HYPERTENSION</b>					
	2,324	1,964	18.4%	18.4%	-
	866	835	3.7%	10.6%	-6.9%
	3,190	2,798	14.0%	16.1%	-2.1%
<b>QPSLIMIT</b>					
	1,135	924	22.8%	22.8%	-
	504	512	-1.6%	2.2%	-3.8%
	1,639	1,437	14.1%	15.4%	-1.3%
<b>UPTRAVI</b>					
	1,120	978	14.5%	14.5%	-
	232	185	25.5%	33.5%	-8.0%
	1,352	1,163	16.3%	17.5%	-1.2%
<b>OTHER PULMONARY HYPERTENSION</b>					
	70	61	14.0%	14.0%	-
	129	137	-5.8%	10.9%	-16.7%
	199	199	0.3%	11.9%	-11.6%
<b>CARDIOVASCULAR / METABOLISM / OTHER</b>					
	2,061	2,254	-8.5%	-8.5%	-
	543	580	-6.4%	-4.6%	-1.8%
	2,605	2,834	-8.1%	-7.7%	-0.4%
<b>XARELTO</b>					
	1,697	1,840	-7.8%	-7.8%	-
	-	-	-	-	-
	1,697	1,840	-7.8%	-7.8%	-
<b>OTHER</b>					
	364	414	-11.9%	-11.9%	-
	543	580	-6.4%	-4.6%	-1.8%
	908	994	-8.7%	-7.7%	-1.0%
<b>TOTAL INNOVATIVE MEDICINE</b>					
	24,993	23,090	8.2%	8.2%	-
	17,639	17,947	-1.7%	2.1%	-3.8%
	\$ 42,632	\$ 41,037	3.9%	5.5%	-1.6%

See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	THIRD QUARTER		% Change		
	2024	2023	Reported	Operational <sup>(1)</sup>	Currency
<b>MEDTECH SEGMENT<sup>(2)</sup></b>					
<b>CARDIOVASCULAR<sup>(4)</sup></b>					
US	\$ 1,148	891	28.6%	28.6%	-
Intl	819	667	22.8%	23.7%	-0.9%
WW	1,966	1,558	26.2%	26.5%	-0.3%
<b>ELECTROPHYSIOLOGY</b>					
US	660	611	7.9%	7.9%	-
Intl	619	549	12.7%	13.8%	-1.1%
WW	1,279	1,161	10.2%	10.7%	-0.5%
<b>ABIOMED</b>					
US	293	254	15.4%	15.4%	-
Intl	68	57	20.1%	20.1%	0.0%
WW	362	311	16.3%	16.3%	0.0%
<b>SHOCKWAVE<sup>(5)</sup></b>					
US	163	-	*	*	-
Intl	66	-	*	*	-
WW	229	-	*	*	-
<b>OTHER CARDIOVASCULAR<sup>(4)</sup></b>					
US	30	26	16.7%	16.7%	-
Intl	66	61	7.7%	7.5%	0.2%
WW	96	87	10.4%	10.2%	0.2%
<b>ORTHOPAEDICS</b>					
US	1,359	1,349	0.7%	0.7%	-
Intl	832	815	2.0%	2.2%	-0.2%
WW	2,191	2,164	1.2%	1.3%	-0.1%
<b>HIPS</b>					
US	250	239	4.8%	4.8%	-
Intl	131	136	-3.6%	-3.2%	-0.4%
WW	381	375	1.7%	1.9%	-0.2%
<b>KNEES</b>					
US	212	207	2.2%	2.2%	-
Intl	140	131	6.9%	7.0%	-0.1%
WW	352	338	4.0%	4.1%	-0.1%
<b>TRAUMA</b>					
US	497	488	1.8%	1.8%	-
Intl	265	253	4.2%	4.8%	-0.6%
WW	761	742	2.6%	2.8%	-0.2%
<b>SPINE, SPORTS &amp; OTHER</b>					
US	400	415	-3.6%	-3.6%	-
Intl	296	295	0.4%	0.4%	0.0%
WW	696	710	-1.9%	-2.0%	0.1%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	NINE MONTHS		% Change		
	2024	2023	Reported	Operational <sup>(1)</sup>	Currency
<b>MEDTECH SEGMENT<sup>(2)</sup></b>					
<b>CARDIOVASCULAR<sup>(4)</sup></b>					
US	\$ 3,292	2,662	23.6%	23.6%	-
Intl	2,353	2,019	16.6%	20.5%	-4.0%
WW	5,645	4,681	20.6%	22.3%	-1.7%
<b>ELECTROPHYSIOLOGY</b>					
US	2,057	1,791	14.8%	14.8%	-
Intl	1,889	1,658	14.0%	18.2%	-4.2%
WW	3,946	3,449	14.4%	16.5%	-2.1%
<b>ABIOMED</b>					
US	905	790	14.5%	14.5%	-
Intl	207	176	17.7%	20.0%	-2.3%
WW	1,112	966	15.1%	15.5%	-0.4%
<b>SHOCKWAVE<sup>(5)</sup></b>					
US	240	-	*	*	-
Intl	66	-	*	*	-
WW	306	-	*	*	-
<b>OTHER CARDIOVASCULAR<sup>(4)</sup></b>					
US	89	81	10.6%	10.6%	-
Intl	192	186	3.0%	5.7%	-2.7%
WW	281	267	5.3%	7.2%	-1.9%
<b>ORTHOPAEDICS</b>					
US	4,229	4,100	3.2%	3.2%	-
Intl	2,614	2,574	1.5%	3.1%	-1.6%
WW	6,843	6,674	2.5%	3.2%	-0.7%
<b>HIPS</b>					
US	785	730	7.5%	7.5%	-
Intl	435	432	0.6%	2.4%	-1.8%
WW	1,220	1,162	5.0%	5.6%	-0.6%
<b>KNEES</b>					
US	684	654	4.5%	4.5%	-
Intl	463	415	11.5%	12.7%	-1.2%
WW	1,147	1,069	7.2%	7.7%	-0.5%
<b>TRAUMA</b>					
US	1,499	1,462	2.5%	2.5%	-
Intl	786	775	1.4%	3.0%	-1.6%
WW	2,285	2,238	2.1%	2.7%	-0.6%
<b>SPINE, SPORTS &amp; OTHER</b>					
US	1,262	1,254	0.6%	0.6%	-
Intl	930	952	-2.3%	-0.6%	-1.7%
WW	2,191	2,205	-0.6%	0.1%	-0.7%

		REPORTED SALES vs. PRIOR PERIOD (\$MM)				
		THIRD QUARTER				
		2024	2023	% Change		
				Reported	Operational <sup>(1)</sup>	Currency
<b>SURGERY</b>						
US		983	994	-1.1%	-1.1%	-
Intl		1,451	1,483	-2.2%	-0.3%	-1.9%
WW		2,434	2,479	-1.8%	-0.7%	-1.1%
<b>ADVANCED</b>						
US		448	455	-1.4%	-1.4%	-
Intl		661	709	-6.8%	-5.1%	-1.7%
WW		1,109	1,164	-4.7%	-3.6%	-1.1%
<b>GENERAL</b>						
US		535	540	-0.9%	-0.9%	-
Intl		791	775	2.1%	4.0%	-1.9%
WW		1,325	1,314	0.8%	2.0%	-1.2%
<b>VISION</b>						
US		549	512	7.2%	7.2%	-
Intl		751	744	0.9%	1.8%	-0.9%
WW		1,300	1,256	3.5%	4.0%	-0.5%
<b>CONTACT LENSES / OTHER</b>						
US		441	399	10.2%	10.2%	-
Intl		527	529	-0.3%	0.6%	-0.9%
WW		968	928	4.2%	4.7%	-0.5%
<b>SURGICAL</b>						
US		108	112	-3.6%	-3.6%	-
Intl		225	216	3.9%	4.7%	-0.8%
WW		333	328	1.3%	1.9%	-0.6%
<b>TOTAL MEDTECH</b>						
US		4,038	3,747	7.8%	7.8%	-
Intl		3,853	3,711	3.9%	5.0%	-1.1%
WW		\$ 7,891	\$ 7,458	5.8%	6.4%	-0.6%

		REPORTED SALES vs. PRIOR PERIOD (\$MM)				
		NINE MONTHS				
		2024	2023	% Change		
				Reported	Operational <sup>(1)</sup>	Currency
<b>SURGERY</b>						
US		2,965	2,984	-0.6%	-0.6%	-
Intl		4,373	4,522	-3.3%	0.4%	-3.7%
WW		7,338	7,507	-2.2%	0.0%	-2.2%
<b>ADVANCED</b>						
US		1,360	1,365	-0.4%	-0.4%	-
Intl		1,977	2,139	-7.6%	-4.2%	-3.4%
WW		3,337	3,504	-4.8%	-2.7%	-2.1%
<b>GENERAL</b>						
US		1,605	1,619	-0.9%	-0.9%	-
Intl		2,397	2,383	0.6%	4.4%	-3.8%
WW		4,001	4,002	0.0%	2.3%	-2.3%
<b>VISION</b>						
US		1,619	1,599	1.3%	1.3%	-
Intl		2,224	2,265	-1.8%	1.0%	-2.8%
WW		3,843	3,864	-0.5%	1.1%	-1.6%
<b>CONTACT LENSES / OTHER</b>						
US		1,288	1,252	2.8%	2.8%	-
Intl		1,508	1,568	-3.8%	-0.4%	-3.4%
WW		2,796	2,820	-0.9%	1.0%	-1.9%
<b>SURGICAL</b>						
US		331	346	-4.4%	-4.4%	-
Intl		717	698	2.7%	4.2%	-1.5%
WW		1,048	1,044	0.3%	1.4%	-1.1%
<b>TOTAL MEDTECH</b>						
US		12,105	11,345	6.7%	6.7%	-
Intl		11,564	11,382	1.6%	4.7%	-3.1%
WW		\$ 23,669	\$ 22,727	4.1%	5.7%	-1.6%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

- \* Percentage greater than 100% or not meaningful
- (1) Operational growth excludes the effect of translational currency
- (2) Unaudited
- (3) Reported as U.S. sales
- (4) Previously referred to as Interventional Solutions
- (5) Acquired on May 31, 2024



Supplemental Sales Information (Unaudited)

(Dollars in Millions)

	THIRD QUARTER					NINE MONTHS				
	2024	2023	Percent Change			2024	2023	Percent Change		
			Total	Operations	Currency			Total	Operations	Currency
<b>Innovative Medicine</b>										
U.S.	\$ 8,871	8,249	7.5	7.5	-	\$ 24,993	23,090	8.2	8.2	-
International	5,709	5,644	1.2	4.4	(3.2)	17,639	17,947	(1.7)	2.1	(3.8)
<b>Worldwide</b>	<b>14,580</b>	<b>13,893</b>	<b>4.9</b>	<b>6.3</b>	<b>(1.4)</b>	<b>42,632</b>	<b>41,037</b>	<b>3.9</b>	<b>5.5</b>	<b>(1.6)</b>
<b>COVID-19 Vaccine</b>										
U.S.	-	-	-	-	-	-	-	-	-	-
International	1	41	(97.7)	(98.9)	1.2	198	1,073	(81.6)	(81.6)	0.0
<b>Worldwide</b>	<b>1</b>	<b>41</b>	<b>(97.7)</b>	<b>(98.9)</b>	<b>1.2</b>	<b>198</b>	<b>1,073</b>	<b>(81.6)</b>	<b>(81.6)</b>	<b>0.0</b>
<b>Innovative Medicine excluding COVID-19 Vaccine</b>										
U.S.	8,871	8,249	7.5	7.5	-	24,993	23,090	8.2	8.2	-
International	5,708	5,603	1.9	5.2	(3.3)	17,441	16,874	3.4	7.4	(4.0)
<b>Worldwide</b>	<b>14,579</b>	<b>13,852</b>	<b>5.2</b>	<b>6.6</b>	<b>(1.4)</b>	<b>42,434</b>	<b>39,964</b>	<b>6.2</b>	<b>7.9</b>	<b>(1.7)</b>
<b>Worldwide</b>										
U.S.	12,909	11,996	7.6	7.6	-	37,098	34,435	7.7	7.7	-
International	9,562	9,355	2.2	4.6	(2.4)	29,203	29,329	(0.4)	3.1	(3.5)
<b>Worldwide</b>	<b>22,471</b>	<b>21,351</b>	<b>5.2</b>	<b>6.3</b>	<b>(1.1)</b>	<b>66,301</b>	<b>63,764</b>	<b>4.0</b>	<b>5.6</b>	<b>(1.6)</b>
<b>COVID-19 Vaccine</b>										
U.S.	-	-	-	-	-	-	-	-	-	-
International	1	41	(97.7)	(98.9)	1.2	198	1,073	(81.6)	(81.6)	0.0
<b>Worldwide</b>	<b>1</b>	<b>41</b>	<b>(97.7)</b>	<b>(98.9)</b>	<b>1.2</b>	<b>198</b>	<b>1,073</b>	<b>(81.6)</b>	<b>(81.6)</b>	<b>0.0</b>
<b>Worldwide</b>										
U.S.	12,909	11,996	7.6	7.6	-	37,098	34,435	7.7	7.7	-
International	9,561	9,314	2.7	5.1	(2.4)	29,005	28,256	2.7	6.3	(3.6)
<b>Worldwide excluding COVID-19 Vaccine</b>	<b>\$ 22,470</b>	<b>21,310</b>	<b>5.4</b>	<b>6.5</b>	<b>(1.1)</b>	<b>\$ 66,103</b>	<b>62,691</b>	<b>5.4</b>	<b>7.1</b>	<b>(1.7)</b>
<b>Europe</b>	<b>\$ 4,914</b>	<b>4,727</b>	<b>4.0</b>	<b>3.0</b>	<b>1.0</b>	<b>\$ 15,291</b>	<b>15,448</b>	<b>(1.0)</b>	<b>(0.7)</b>	<b>(0.3)</b>
Europe COVID-19 Vaccine Sales	1	41	(97.7)	(98.9)	1.2	198	1,073	(81.6)	(81.6)	0.0
<b>Europe excluding COVID-19 Vaccine Sales</b>	<b>\$ 4,913</b>	<b>4,686</b>	<b>4.8</b>	<b>3.8</b>	<b>1.0</b>	<b>\$ 15,093</b>	<b>14,375</b>	<b>5.0</b>	<b>5.3</b>	<b>(0.3)</b>

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

THIRD QUARTER

	2024		2023		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 22,471	100.0	\$ 21,351	100.0	5.2
Cost of products sold	6,963	31.0	6,606	30.9	5.4
Gross Profit	15,508	69.0	14,745	69.1	5.2
Selling, marketing and administrative expenses	5,478	24.3	5,400	25.3	1.4
Research and development expense	4,952	22.0	3,447	16.2	43.7
In-process research and development impairments	-	-	206	1.0	
Interest (income) expense, net	(99)	(0.4)	(182)	(0.8)	
Other (income) expense, net	1,798	8.0	499	2.3	
Restructuring	41	0.2	158	0.7	
Earnings before provision for taxes on income	3,338	14.9	5,217	24.4	(36.0)
Provision for taxes on income	644	2.9	908	4.2	(29.1)
Net earnings from Continuing Operations	\$ 2,694	12.0	\$ 4,309	20.2	(37.5)
Net earnings from Discontinued Operations, net of tax	-		21,719		
Net earnings	\$ 2,694		\$ 26,028		
Net earnings per share (Diluted) from Continuing Operations	\$ 1.11		\$ 1.69		(34.3)
Net earnings per share (Diluted) from Discontinued Operations	\$ -		\$ 8.52		
Average shares outstanding (Diluted)	2,427.9		2,549.7		
Effective tax rate from Continuing Operations	19.3 %		17.4 %		
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income from Continuing Operations	\$ 7,277	32.4	\$ 8,033	37.6	(9.4)
Net earnings from Continuing Operations	\$ 5,876	26.1	\$ 6,777	31.7	(13.3)
Net earnings per share (Diluted) from Continuing Operations	\$ 2.42		\$ 2.66		(9.0)
Effective tax rate from Continuing Operations	19.3 %		15.6 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

NINE MONTHS

	2024		2023		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 66,301	100.0	\$ 63,764	100.0	4.0
Cost of products sold	20,343	30.7	19,755	31.0	3.0
Gross Profit	45,958	69.3	44,009	69.0	4.4
Selling, marketing and administrative expenses	16,416	24.8	15,702	24.6	4.5
Research and development expense	11,934	18.0	10,605	16.6	12.5
In-process research and development impairments	194	0.3	255	0.4	
Interest (income) expense, net	(433)	(0.7)	(277)	(0.4)	
Other (income) expense, net	4,855	7.3	7,055	11.1	
Restructuring	192	0.3	433	0.6	
Earnings before provision for taxes on income	12,800	19.3	10,236	16.1	25.0
Provision for taxes on income	2,165	3.3	1,042	1.7	107.8
Net earnings from Continuing Operations	\$ 10,635	16.0	\$ 9,194	14.4	15.7
Net earnings from Discontinued Operations, net of tax	-		21,910		
Net earnings	\$ 10,635		\$ 31,104		
Net earnings per share (Diluted) from Continuing Operations	\$ 4.38		\$ 3.53		24.1
Net earnings per share (Diluted) from Discontinued Operations	\$ -		\$ 8.42		
Average shares outstanding (Diluted)	2,429.5		2,603.4		
Effective tax rate from Continuing Operations	16.9 %		10.2 %		
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income from Continuing Operations	\$ 23,558	35.5	\$ 23,574	37.0	(0.1)
Net earnings from Continuing Operations	\$ 19,296	29.1	\$ 19,847	31.1	(2.8)
Net earnings per share (Diluted) from Continuing Operations	\$ 7.94		\$ 7.62		4.2
Effective tax rate from Continuing Operations	18.1 %		15.8 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Adjusted Operational Sales Growth  
THIRD QUARTER 2024 ACTUAL vs. 2023 ACTUAL

	Segments		
	Innovative Medicine	MedTech	Total
<b>WW As Reported</b>	<b>4.9%</b>	<b>5.8%</b>	<b>5.2%</b>
U.S.	7.5%	7.8%	7.6%
International	1.2%	3.9%	2.2%
<b>WW Currency</b>	<b>(1.4)</b>	<b>(0.6)</b>	<b>(1.1)</b>
U.S.	-	-	-
International	(3.2)	(1.1)	(2.4)
<b>WW Operational</b>	<b>6.3%</b>	<b>6.4%</b>	<b>6.3%</b>
U.S.	7.5%	7.8%	7.6%
International	4.4%	5.0%	4.6%
<b>Shockwave</b>		<b>(3.1)</b>	<b>(1.1)</b>
U.S.		(4.4)	(1.4)
International		(1.8)	(0.7)
<b>All Other Acquisitions and Divestitures (A&amp;D)</b>	<b>0.1</b>	<b>0.4</b>	<b>0.2</b>
U.S.	0.1	0.8	0.3
International	0.2	0.0	0.1
<b>WW Adjusted Operational Ex A&amp;D</b>	<b>6.4%</b>	<b>3.7%</b>	<b>5.4%</b>
U.S.	7.6%	4.2%	6.5%
International	4.6%	3.2%	4.0%
<b>COVID-19 Vaccine</b>	<b>0.3</b>		<b>0.2</b>
U.S.	0.0		0.0
International	0.8		0.5
<b>WW Adjusted Operational Ex A&amp;D &amp; COVID-19 Vaccine</b>	<b>6.7%</b>	<b>3.7%</b>	<b>5.6%</b>
U.S.	7.6%	4.2%	6.5%
International	5.4%	3.2%	4.5%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth  
NINE MONTHS 2024 ACTUAL vs. 2023 ACTUAL

Segments			
	Innovative Medicine	MedTech	Total
<b>WW As Reported</b>	<b>3.9%</b>	<b>4.1%</b>	<b>4.0%</b>
U.S.	8.2%	6.7%	7.7%
International	(1.7)%	1.6%	(0.4)%
<b>WW Currency</b>	<b>(1.6)</b>	<b>(1.6)</b>	<b>(1.6)</b>
U.S.	-	-	-
International	(3.8)	(3.1)	(3.5)
<b>WW Operational</b>	<b>5.5%</b>	<b>5.7%</b>	<b>5.6%</b>
U.S.	8.2%	6.7%	7.7%
International	2.1%	4.7%	3.1%
<b>Shockwave</b>		<b>(1.3)</b>	<b>(0.5)</b>
U.S.		(2.1)	(0.7)
International		(0.6)	(0.2)
<b>All Other Acquisitions and Divestitures (A&amp;D)</b>	<b>0.1</b>	<b>0.3</b>	<b>0.2</b>
U.S.	0.1	0.7	0.3
International	0.1	0.1	0.1
<b>WW Adjusted Operational Ex A&amp;D</b>	<b>5.6%</b>	<b>4.7%</b>	<b>5.3%</b>
U.S.	8.3%	5.3%	7.3%
International	2.2%	4.2%	3.0%
<b>COVID-19 Vaccine</b>	<b>2.4</b>		<b>1.5</b>
U.S.	0.0		0.0
International	5.3		3.2
<b>WW Adjusted Operational Ex A&amp;D &amp; COVID-19 Vaccine</b>	<b>8.0%</b>	<b>4.7%</b>	<b>6.8%</b>
U.S.	8.3%	5.3%	7.3%
International	7.5%	4.2%	6.2%

Note: Percentages are based on actual, non-rounded figures and may not sum

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measures

(Dollars in Millions Except Per Share Data)	Third Quarter		Nine Months Ended	
	2024	2023	2024	2023
Net Earnings from Continuing Operations, after tax- as reported	<b>\$2,694</b>	<b>\$4,309</b>	<b>\$10,635</b>	<b>\$9,194</b>
<i>Pre-tax Adjustments</i>				
Litigation related	2,388	(51)	5,466	6,986
Intangible Asset Amortization expense	1,171	1,132	3,355	3,384
COVID-19 Vaccine related costs <sup>1</sup>	4	44	77	653
Restructuring related <sup>2</sup>	47	384	207	659
Medical Device Regulation <sup>3</sup>	38	74	157	223
Acquisition, integration and divestiture related	328	22	928	102
(Gains)/losses on securities	(37)	1,005	374	1,076
IPR&D impairments	-	206	194	255
<i>Tax Adjustments</i>				
Tax impact on special item adjustments <sup>4</sup>	(762)	(482)	(2,055)	(2,769)
Tax legislation and other tax related	5	134	(42)	84
Adjusted Net Earnings from Continuing Operations, after tax	<b>\$5,876</b>	<b>\$6,777</b>	<b>\$19,296</b>	<b>\$19,847</b>
Average shares outstanding (Diluted)	2,427.9	2,549.7	2,429.5	2,603.4
Adjusted net earnings per share from Continuing Operations (Diluted)	<b>\$2.42</b>	<b>\$2.66</b>	<b>\$7.94</b>	<b>\$7.62</b>
Operational adjusted net earnings per share from Continuing Operations (Diluted)	<b>\$2.41</b>		<b>\$7.94</b>	

Notes:

- COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.
- In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of \$19 million in the fiscal third quarter of 2024 (\$100 million Q3 2024 YTD) and \$149 million in the fiscal third quarter of 2023 (\$424 million Q3 2023 YTD) includes the termination of partnered and non-partnered program costs, asset impairments and asset divestments.  
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of \$28 million in the fiscal third quarter of 2024 (\$107 million Q3 2024 YTD) and \$235 million in the fiscal third quarter of 2023 (\$235 million Q3 2023 YTD) primarily includes inventory and instrument reserves related to the market and product exits.
- European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company's previously registered products.** MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which will be completed by the end of 2024.
- The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measures

Q3 QTD - Income Before Tax and Research & Development Expense by Segment  
Dollars in Millions

		Innovative Medicine		MedTech		Unallocated		Worldwide Total	
		2024	2023	2024	2023	2024	2023	2024	2023
Reported Income Before Tax by Segment From Continuing Operations	\$	4,482	4,794	1,059	1,185	(2,203)	(762)	3,338	5,217
% to Sales		<b>30.7%</b>	<b>34.5%</b>	<b>13.4%</b>	<b>15.9%</b>	<b>-9.8%</b>	<b>-3.6%</b>	<b>14.9%</b>	<b>24.4%</b>
Intangible asset amortization expense		695	749	476	383	-	-	1,171	1,132
In-process research and development impairments		-	206	-	-	-	-	-	206
Litigation related		356	(32)	19	(19)	2,013	-	2,388	(51)
Loss/(gain) on securities		(41)	398	4	(38)	-	645	(37)	1,005
Restructuring related		19	149	28	235	-	-	47	384
Acquisition, integration and divestiture related		6	-	277	22	45	-	328	22
Medical Device Regulation		-	-	38	74	-	-	38	74
COVID-19 Vaccine related costs		4	44	-	-	-	-	4	44
Adjusted Income Before Tax by Segment From Continuing Operations	\$	<u>5,521</u>	<u>6,308</u>	<u>1,901</u>	<u>1,842</u>	<u>(145)</u>	<u>(117)</u>	<u>7,277</u>	<u>8,033</u>
% to Sales		<b>37.9%</b>	<b>45.4%</b>	<b>24.1%</b>	<b>24.7%</b>	<b>-0.6%</b>	<b>-0.5%</b>	<b>32.4%</b>	<b>37.6%</b>
Estimated as of 10/15/2024									
As Reported Research and development expense*	\$	4,213	2,778	739	669			4,952	3,447
% to Sales		<b>28.9%</b>	<b>20.0%</b>	<b>9.4%</b>	<b>9.0%</b>			<b>22.0%</b>	<b>16.2%</b>

\*Includes payment to secure the global rights for NM26 Bi-specific Antibody in Q3 2024

1,250

1,250

Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measures

Q3 YTD - Income Before Tax and Research & Development Expense by Segment  
Dollars in Millions

		Innovative Medicine		MedTech		Unallocated		Worldwide Total	
		2024	2023	2024	2023	2024	2023	2024	2023
Reported Income Before Tax by Segment From Continuing Operations	\$	14,910	14,008	3,668	4,265	(5,778)	(8,037)	12,800	10,236
% to Sales		<b>35.0%</b>	<b>34.1%</b>	<b>15.5%</b>	<b>18.8%</b>	<b>-8.7%</b>	<b>-12.6%</b>	<b>19.3%</b>	<b>16.1%</b>
Intangible asset amortization expense		2,087	2,236	1,268	1,148	-	-	3,355	3,384
In-process research and development impairments		194	206	-	49	-	-	194	255
Litigation related		399	(125)	15	41	5,052	7,070	5,466	6,986
Loss/(gain) on securities		(26)	474	48	(43)	352	645	374	1,076
Restructuring related		100	424	107	235	-	-	207	659
Acquisition, integration and divestiture related		54	-	747	102	127	-	928	102
Medical Device Regulation		-	-	157	223	-	-	157	223
COVID-19 Vaccine related costs		77	653	-	-	-	-	77	653
Adjusted Income Before Tax by Segment From Continuing Operations	\$	<u>17,795</u>	<u>17,876</u>	<u>6,010</u>	<u>6,020</u>	<u>(247)</u>	<u>(322)</u>	<u>23,558</u>	<u>23,574</u>
% to Sales		<b>41.7%</b>	<b>43.6%</b>	<b>25.4%</b>	<b>26.5%</b>	<b>-0.4%</b>	<b>-0.5%</b>	<b>35.5%</b>	<b>37.0%</b>
Estimated as of 10/15/2024									
As Reported Research and development expense*	\$	9,831	8,604	2,103	2,001			11,934	10,605
% to Sales		<b>23.1%</b>	<b>21.0%</b>	<b>8.9%</b>	<b>8.8%</b>			<b>18.0%</b>	<b>16.6%</b>

\*Includes payment to secure the global rights for NM26 Bi-specific Antibody in Q3 2024

1,250

1,250



Johnson & Johnson and Subsidiaries  
GAAP to Non-GAAP Reconciliation  
\$ in Millions

Quarter to Date

	Third Quarter Sept. 29, 2024 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Third Quarter Sept. 29, 2024 Non-GAAP
Cost of products sold	\$ 6,963	(1,171)			(6)	(156)		(16)	(2)	-	5,612
Selling, marketing and admin expenses	5,478							(3)			5,475
Research and development expense	4,952					(36)		(19)	(2)		4,895
Other (Income) / Expense	1,798	-	(2,388)		-	(136)	37		-		(689)
In-process research and development impairments	-			-		-					-
Restructuring	41				(41)						-
Provision for taxes on income	644	169	527	-	9	59	(9)	6	1	(5)	1,401
Net Earnings from Continuing Operations	2,694	1,002	1,861	-	38	269	(28)	32	3	5	5,876

	Third Quarter Oct. 1, 2023 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Third Quarter Oct. 1, 2023 Non-GAAP
Cost of products sold	\$ 6,606	(1,132)			(226)			(34)	(9)	-	5,205
Selling, marketing and admin expenses	5,400							(6)			5,394
Research and development expense	3,447					-		(33)	(36)		3,378
Other (Income) / Expense	499	-	51		-	(22)	(1,005)		-		(477)
In-process research and development impairments	206			(206)							-
Restructuring	158				(158)						-
Provision for taxes on income	908	178	(12)	46	72	5	167	14	12	(134)	1,256
Net Earnings from Continuing Operations	4,309	954	(39)	160	312	17	838	59	33	134	6,777

Year to Date

	Nine Months Sept. 29, 2024 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Nine Months Sept. 29, 2024 Non-GAAP
Cost of products sold	\$ 20,343	(3,355)			(15)	(206)		(66)	(8)		16,693
Selling, marketing and admin expenses	16,416							(12)	-		16,404
Research and development expense	11,934					(69)		(79)	(19)		11,767
Other (Income) / Expense	4,855	-	(5,466)		-	(653)	(374)		(50)		(1,688)
In-process research and development impairments	194			(194)		-			-		-
Restructuring	192				(192)						-
Provision for taxes on income	2,165	473	1,224	43	42	222	5	29	17	42	4,262
Net Earnings from Continuing Operations	10,635	2,882	4,242	151	165	706	369	128	60	(42)	19,296

	Nine Months Oct. 1, 2023 GAAP	Intangible asset amortization	Litigation related	In-process research and development impairments	Restructuring related	Acquisition, integration and divestiture related	(Loss)/gain on securities	Medical Device Regulation	COVID-19 Vaccine Related Costs	Tax legislation and other tax related	Nine Months Oct. 1, 2023 Non-GAAP
Cost of products sold	\$ 19,755	(3,380)			(226)			(91)	(177)		15,881
Selling, marketing and admin expenses	15,702							(21)			15,681
Research and development expense	10,605					(16)		(111)	(98)		10,380
Other (Income) / Expense	7,055	(4)	(6,986)		-	(86)	(1,076)		(378)		(1,475)
In-process research and development impairments	255			(255)		-					-
Restructuring	433				(433)						-
Provision for taxes on income	1,042	532	1,639	57	141	22	182	41	155	(84)	3,727
Net Earnings from Continuing Operations	9,194	2,852	5,347	198	518	80	894	182	498	84	19,847